JP2009501744A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009501744A5 JP2009501744A5 JP2008521868A JP2008521868A JP2009501744A5 JP 2009501744 A5 JP2009501744 A5 JP 2009501744A5 JP 2008521868 A JP2008521868 A JP 2008521868A JP 2008521868 A JP2008521868 A JP 2008521868A JP 2009501744 A5 JP2009501744 A5 JP 2009501744A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- salt
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- LAQGPQNMQRFDIM-GOSISDBHSA-N 4-(2,4-difluorobenzoyl)-1-[4-[3-[(2r)-2-methylpyrrolidin-1-yl]propoxy]phenyl]piperazin-2-one Chemical compound C[C@@H]1CCCN1CCCOC1=CC=C(N2C(CN(CC2)C(=O)C=2C(=CC(F)=CC=2)F)=O)C=C1 LAQGPQNMQRFDIM-GOSISDBHSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000938 histamine H1 antagonist Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0514811.9A GB0514811D0 (en) | 2005-07-19 | 2005-07-19 | Compounds |
| PCT/EP2006/007034 WO2007009739A1 (en) | 2005-07-19 | 2006-07-17 | Compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009501744A JP2009501744A (ja) | 2009-01-22 |
| JP2009501744A5 true JP2009501744A5 (enExample) | 2009-09-10 |
Family
ID=34897469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008521868A Pending JP2009501744A (ja) | 2005-07-19 | 2006-07-17 | 化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20080207638A1 (enExample) |
| EP (1) | EP1904484B1 (enExample) |
| JP (1) | JP2009501744A (enExample) |
| AT (1) | ATE440836T1 (enExample) |
| DE (1) | DE602006008788D1 (enExample) |
| ES (1) | ES2330472T3 (enExample) |
| GB (1) | GB0514811D0 (enExample) |
| WO (1) | WO2007009739A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008321823B2 (en) * | 2007-11-13 | 2013-03-07 | Taisho Pharmaceutical Co., Ltd. | Phenylpyrazole derivatives |
| US20110160249A1 (en) | 2008-05-23 | 2011-06-30 | Schaab Kevin Murray | 5-lipoxygenase-activating protein inhibitor |
| JP5740838B2 (ja) * | 2009-05-12 | 2015-07-01 | 大正製薬株式会社 | フェニルピラゾール誘導体 |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| JP6110611B2 (ja) | 2012-07-18 | 2017-04-05 | 株式会社東芝 | アミンの回収方法および分析方法 |
| EA201692111A1 (ru) | 2014-05-12 | 2017-08-31 | Глаксосмитклайн Интеллекчуал Проперти (№ 2) Лимитед | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний |
| JP2023519585A (ja) | 2020-03-26 | 2023-05-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | ウイルス感染を予防または治療するカテプシン阻害剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19614204A1 (de) * | 1996-04-10 | 1997-10-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| WO2002006223A1 (en) * | 2000-07-13 | 2002-01-24 | Abbott Laboratories | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| US6620839B2 (en) * | 2000-07-13 | 2003-09-16 | Abbott Laboratories | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| GB0514812D0 (en) * | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
-
2005
- 2005-07-19 GB GBGB0514811.9A patent/GB0514811D0/en not_active Ceased
-
2006
- 2006-07-17 WO PCT/EP2006/007034 patent/WO2007009739A1/en not_active Ceased
- 2006-07-17 US US11/995,927 patent/US20080207638A1/en not_active Abandoned
- 2006-07-17 ES ES06791540T patent/ES2330472T3/es active Active
- 2006-07-17 AT AT06791540T patent/ATE440836T1/de not_active IP Right Cessation
- 2006-07-17 DE DE602006008788T patent/DE602006008788D1/de not_active Expired - Fee Related
- 2006-07-17 EP EP06791540A patent/EP1904484B1/en active Active
- 2006-07-17 JP JP2008521868A patent/JP2009501744A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017528507A5 (enExample) | ||
| JP2013523733A5 (enExample) | ||
| JP2015512931A5 (enExample) | ||
| JP2014521735A5 (enExample) | ||
| JP2017528503A5 (enExample) | ||
| JP2012507535A5 (enExample) | ||
| JP2008501000A5 (enExample) | ||
| JP2010529118A5 (enExample) | ||
| JP2012530705A5 (enExample) | ||
| JP2012533546A5 (enExample) | ||
| JP2006143751A5 (enExample) | ||
| JP2011522816A5 (enExample) | ||
| JP2013519675A5 (enExample) | ||
| JP2012508734A5 (enExample) | ||
| HRP20120144T1 (en) | Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity | |
| JP2009545527A5 (enExample) | ||
| JP2009511568A5 (enExample) | ||
| JP2014502979A5 (enExample) | ||
| CN109982699A (zh) | 一种mor激动剂与kor激动剂的药物组合物及其用途 | |
| JP2013506674A5 (enExample) | ||
| JP2009501745A5 (enExample) | ||
| JP2008513510A5 (enExample) | ||
| JP2016522254A5 (enExample) | ||
| JP2009532434A5 (enExample) | ||
| JP2014518212A5 (ja) | 化合物及び組成物 |